New combo aims to wipe out hidden breast cancer cells after standard treatment
NCT ID NCT04333706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug sarilumab to chemotherapy (capecitabine) can eliminate tiny amounts of cancer left behind after standard treatment in people with triple negative breast cancer, a very aggressive type. The goal is to prevent the cancer from coming back and improve survival. About 65 adults with high-risk or metastatic breast cancer will take part. The study has two phases: first finding the safest dose, then checking if the treatment clears cancer cells from the blood and bone marrow.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Los Angeles General Medical Center
RECRUITINGLos Angeles, California, 90033, United States
-
UF Health
ACTIVE_NOT_RECRUITINGGainesville, Florida, 32610, United States
-
USC/Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare
- Can simple positive activities boost Well-Being in cancer care?